Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial
Santamaria A et al., 2015
The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 29(19), 3234-3237
To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women.
Methods
In an open-label, randomized trial, myo-inositol (2 g plus 200 μg folic acid twice a day) or placebo (200 μg folic acid twice a day) was administered from the first trimester to delivery in pregnant overweight non-obese women (pre-pregnancy body mass index ≥ 25 and < 30 kg/m(2)). The primary outcome was the incidence of GDM.
Results
From January 2012 to December 2014, 220 pregnant women were randomized at two Italian University hospitals, 110 to myo-inositol and 110 to placebo. The incidence of GDM was significantly lower in the myo-inositol group compared to the placebo group (11.6% versus 27.4%, respectively, p = 0.004). Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70).
Conclusions
Myo-inositol supplementation, administered since early pregnancy, reduces GDM incidence in overweight non-obese women.
Santamaria, A., Petrella, E., Pintaudi, B., Corrado, F., D'Anna, R., Neri, I., Facchinetti, F., & Di Benedetto, A. (2015). Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*, *29*(19), 3234-3237. https://doi.org/10.3109/14767058.2015.1121478
Santamaria A, Petrella E, Pintaudi B, Corrado F, D'Anna R, Neri I, et al. Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. J Matern Fetal Neonatal Med. 2015;29(19):3234-3237. doi:10.3109/14767058.2015.1121478
Santamaria, A., et al. "Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial." *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians*, vol. 29, no. 19, 2015, pp. 3234-3237.
Myrer RS et al., 2025The Utah women's health review
Objectives: The objective of this study is to test the association between preconception polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM) using Utah's Pregnancy Risk Assessment...
Pineles BL et al., 2023
Open Access
AJOG Global Reports
Background: Cesarean delivery is a major source of maternal morbidity, and repeat cesarean delivery accounts for 40% of cesarean delivery, but recent data on the trial of labor after cesarean and vagi...
Bergh E et al., 2021Obstetrics and Gynecology Clinics of North America
The field of fetal medicine has evolved significantly over the past several decades. Our ability to identify and treat the unborn patient has been shaped by advancements in imaging technology, genetic...
Dawood AS et al., 2018
Open Access
Clinical and Experimental Reproductive Medicine
The purpose of this paper is to review the current clinical uses of platelet-rich plasma (PRP) in the field of gynecology. All relevant articles published from January 2000 to December 2017 were revie...